EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Feasibility Study of Combined Systemic Therapy and Carbon‐Ion Radiotherapy for Hepatocellular Carcinoma Patients

Daijiro Kobayashi, Kei Shibuya iD, Yuhei Miyasaka, Kenichiro Araki iD, Yuichi Yamazaki, Ken Shirabe iD, Tatsuya Ohno

Cancer Medicine · 2026-07 · 15 (7)

DOI: 10.1002/cam4.72068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 26.06.2026. Verfasst von Daijiro Kobayashi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Heavy Ion Radiotherapy, Protein Kinase Inhibitors. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent advances in systemic therapy, including tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), have improved outcomes for hepatocellular carcinoma (HCC) and enabled downstaging strategies that allow subsequent local treatments. Carbon‐ion radiotherapy (CIRT) can provide excellent tumor control with minimal impairment of liver function. However, the feasibility and safety of combining systemic therapy with CIRT have not been well evaluated.

Methods

We retrospectively reviewed 21 patients with HCC who received CIRT integrated with systemic therapy at a single institution. Systemic therapy consisted of TKIs or ICIs and was administered either before or after CIRT, reflecting real‐world clinical practice. The primary endpoint was feasibility and safety, assessed by the incidence of adverse events (AEs) graded by CTCAE v5.0 and changes in albumin–bilirubin (ALBI) and Child–Pugh scores. Secondary endpoints included overall survival (OS), progression‐free survival (PFS), and local control (LC).

Results

No grade ≥ 4 AEs were observed during peri‐radiotherapeutic integration of systemic therapy and CIRT. The most frequent AEs were grade 1 fatigue, radiation pneumonitis, and hepatobiliary disorders. Neither ALBI nor Child–Pugh scores showed clinically meaningful deterioration after CIRT, indicating preserved liver function. The 1‐year OS, PFS, and LC rates were 59.0%, 28.6%, and 70.6%, respectively. Despite large tumor burdens (median GTV 93.2 cm 3 ) and variable baseline liver function, treatment was generally well tolerated.

Conclusions

Integration of CIRT with systemic therapy was feasible and demonstrated an acceptable safety profile without worsening liver function. This multimodal approach may represent a treatment option for selected patients with HCC, particularly in downstaging or locally advanced settings. Prospective studies are needed to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver NeoplasmsCarcinoma, HepatocellularHeavy Ion RadiotherapyProtein Kinase InhibitorsImmune Checkpoint InhibitorsHumansFemaleMaleFeasibility StudiesAgedMiddle AgedRetrospective StudiesCombined Modality TherapyTreatment OutcomeAged, 80 and overAdult

Stichwörter der Autor:innen

carbon‐ion radiotherapyhepatocellular carcinomaimmune checkpoint inhibitorsystemic therapytyrosine kinase inhibitor

Substanzen

Protein Kinase InhibitorsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
  • Division of Hepatobiliary and Pancreatic Surgery, Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
  • Department of Gastroenterology and Hepatology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.

ORCID-Profile: Kei Shibuya, Kenichiro Araki, Ken Shirabe

Zitieren

APA

Kobayashi, D., Shibuya, K., Miyasaka, Y., Araki, K., Yamazaki, Y., Shirabe, K., & Ohno, T. (2026). Feasibility Study of Combined Systemic Therapy and Carbon‐Ion Radiotherapy for Hepatocellular Carcinoma Patients. Cancer Medicine, 15(7). https://doi.org/10.1002/cam4.72068

Vancouver

Kobayashi D, Shibuya K, Miyasaka Y, Araki K, Yamazaki Y, Shirabe K, et al. Feasibility Study of Combined Systemic Therapy and Carbon‐Ion Radiotherapy for Hepatocellular Carcinoma Patients. Cancer Medicine. 2026;15(7). doi:10.1002/cam4.72068

BibTeX
@article{Kobayashi2026,
  author = {Kobayashi, Daijiro and Shibuya, Kei and Miyasaka, Yuhei and Araki, Kenichiro and Yamazaki, Yuichi and Shirabe, Ken and Ohno, Tatsuya},
  title = {Feasibility Study of Combined Systemic Therapy and Carbon‐Ion Radiotherapy for Hepatocellular Carcinoma Patients},
  journal = {Cancer Medicine},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.1002/cam4.72068}
}
Kostenlos starten →